je.st
news
Sub-Optimal 39% Hep C Cure Rate Keeps Merck In Gilead's Rear View
2014-11-13 14:42:27| Biotech - Topix.net
Until Merck's product can deliver an optimal cure rate at a cheaper price, it poses no threat to Gilead's Harvoni. Merck's attempt to compete with Gilead in finding a cure for hepatitis C has fallen short .
Tags: view
rate
rear
cure
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||